Guidance on the use of paclitaxel in the treatment of ovarian cancer

Technology appraisal guidance
Reference number: TA55
Published: 22 January 2003
Last updated: 01 May 2005

History

Other information

Summary: Guidance on the use of paclitaxel in the treatment of ovarian cancer information
Summary (PDF 63 KB)

Published:

18 November 2010

Background information

Ovarian cancer - paclitaxel (review): static list review decision - August 2015 information
Ovarian cancer - paclitaxel (review): appendix A - static list review paper - August 2015 (PDF 200 KB)

Published:

10 August 2015
Review Decision - October 2009 information
Review decision - October 2009: appendix A - decision paper considered by the Institute's Guidance Executive (PDF 79 KB)

Published:

15 October 2009
Review Proposal - August 2009 information
Review proposal - August 2009: appendix A - provisional matrix (PDF 37 KB)

Published:

18 August 2009
Review proposal - August 2009: appendix B - proposal paper (PDF 167 KB)

Published:

18 August 2009
Decision of the Appeal Panel: Appraisal of Paclitaxel for Ovarian Cancer (PDF 80 KB)

Published:

24 December 2002
Assessment Report: An update of a rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of ovarian cancer (PDF 1.15 MB)

Published:

22 January 2003
Review update on the use of paclitaxel (1st line only) in the treatment of ovarian cancer (PDF 19 KB)

Published:

13 December 2005

Update - Review of Taxanes for Breast and Ovarian Cancer 19.04.01

Update - Review of Taxanes for Breast and Ovarian Cancer 19.04.01 information